Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Potentially Nephroprotective Effects of Carnitine and Phosphodiesterase Type 5 (PDE5) Inhibitor Agent Against Contrast Media-induced Nephropathy (CMN): A Double Blind Randomized Study

NCT01564303 is registered in ClinicalTrials.gov with The Nazareth Hospital as lead sponsor.

NCT NCT01564303
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01564303 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Potentially Nephroprotective Effects of Carnitine and Phosphodiesterase Type 5 (PDE5) Inhibitor Agent Against Contrast Media-induced Nephropathy (CMN): A Double Blind Randomized Study
Lead sponsor
The Nazareth Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
May 31, 2012
Completion date
February 28, 2013
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

contrast media induced nephropathy